Last reviewed · How we verify
NCT06584123: FET-pit-PET
Molecular Pituitary Imaging Using 18F-FET PET
NA trial testing 18F-Fluoro-ethyl-tyrosine (FET) PET in Pituitary Adenoma in 20 participants. Currently enrolling.
2 September 2026
Quick facts
| Lead sponsor | University of Cambridge |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 20 |
| Start date | 3 September 2024 |
| Primary completion | 2 September 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- 18F-Fluoro-ethyl-tyrosine (FET) PET
Conditions studied
- Pituitary Adenoma — all drugs for Pituitary Adenoma →
Sponsor
University of Cambridge
Who can join
Adults 18 to 100, any sex, with Pituitary Adenoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this single centre pilot study is to explore whether 18F-fluoro-ethyl-tyrosine PET (FET-PET) yields comparable findings to 11C-methionine PET (Met-PET) for the localisation of pituitary tumours.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06584123
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pituitary Adenoma
Currently open trials in the same condition.
- NCT04569591 — DDAVP for Pituitary Adenoma · NA · recruiting
- NCT06831461 — Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors · NA · recruiting
- NCT06973824 — A Twenty-years' Experience in Pituitary Disease. · recruiting
- NCT06679816 — Hydrocortisone in Hormone Replacement Therapy for Large Pituitary Neuroendocrine Tumors · Phase 4 · recruiting
- NCT05727605 — Neurocognition After Radiotherapy in CNS- and Skull-base Tumors · NA · recruiting
Other University of Cambridge trials
Trials by the same sponsor.
- NCT07106216 — Evaluating Near-infrared Spectroscopy Devices for Monitoring Traumatic Brain Injury · not yet recruiting
- NCT07341230 — Deep Brain Stimulation to Understand and Treat Addiction · NA · recruiting
- NCT07154836 — Call for Life: Exploring mHealth Solutions for Enhancing Childhood Vaccinations Among Displaced Children in Conflict-aff · NA · enrolling by invitation
- NCT06844539 — taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs · NA · recruiting
- NCT07026656 — Pre-clinical Diagnosis Using Integrated Microbial and Host Response Signatures to Improve Outcomes From Ventilator-assoc · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06584123 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Cambridge
- Last refreshed: 6 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06584123.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing